{"id":73483,"date":"2026-06-03T09:46:46","date_gmt":"2026-06-03T09:46:46","guid":{"rendered":"https:\/\/crowdfundjunction.com\/blog\/coinbase-ceo-brian-armstrongs-newlimit-raises-435-million-tripling-valuation-to-3-1-billion\/"},"modified":"2026-06-03T09:46:46","modified_gmt":"2026-06-03T09:46:46","slug":"coinbase-ceo-brian-armstrongs-newlimit-raises-435-million-tripling-valuation-to-3-1-billion","status":"publish","type":"post","link":"https:\/\/crowdfundjunction.com\/blog\/coinbase-ceo-brian-armstrongs-newlimit-raises-435-million-tripling-valuation-to-3-1-billion\/","title":{"rendered":"Coinbase CEO Brian Armstrong&#8217;s Newlimit Raises $435 Million, Tripling Valuation to $3.1 Billion"},"content":{"rendered":"<p><b>(Originally posted on : Bitcoin News )<\/b><br \/>\n<\/p>\n<div>\n<p><span style=\"font-weight:400\"><\/p>\n<div class=\"@container mb-[25px] rounded-sm overflow-clip py-0.5 pr-0.5 pl-2.5 bg-success-100\">\n<div class=\"flex flex-col gap-m overflow-clip rounded-[6px] !bg-success-10 p-3 @[420px]:p-m\">\n<h2 class=\"m-0 flex items-center gap-s text-[19px] !text-[#1c1c1c] md:text-[20px]\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"16\" height=\"10\" viewbox=\"0 0 16 10\" fill=\"none\" class=\"shrink-0 text-success-100\" aria-hidden=\"true\"><path d=\"M1 1.5h14\" stroke=\"currentColor\" stroke-width=\"2.5\" stroke-linecap=\"round\"\/><path d=\"M1 8.5h10\" stroke=\"currentColor\" stroke-width=\"2.5\" stroke-linecap=\"round\"\/><\/svg><span>Key Takeaways<\/span><\/h2>\n<ul class=\"m-0 flex list-none flex-col gap-m pl-0\">\n<li class=\"m-0 flex items-start gap-s !text-[#434248]\"><span class=\"mt-2 size-2 shrink-0 rounded-full bg-success-100\" aria-hidden=\"true\"\/><span class=\"text-body\">Newlimit raised a $435 million Series C led by Founders Fund, announced June 2.<\/span><\/li>\n<li class=\"m-0 flex items-start gap-s !text-[#434248]\"><span class=\"mt-2 size-2 shrink-0 rounded-full bg-success-100\" aria-hidden=\"true\"\/><span class=\"text-body\">The round lifted the biotech\u2019s valuation to about $3.1 billion, roughly triple its prior mark.<\/span><\/li>\n<li class=\"m-0 flex items-start gap-s !text-[#434248]\"><span class=\"mt-2 size-2 shrink-0 rounded-full bg-success-100\" aria-hidden=\"true\"\/><span class=\"text-body\">Newlimit plans to bring its first cell-aging reprogramming medicine into human trials next year.<\/span><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p><\/span><\/p>\n<h2><span style=\"font-weight:400\"> <span>Crypto<\/span> Wealth Flows Into Longevity Science<\/span><\/h2>\n<p><span style=\"font-weight:400\">Newlimit, the anti-aging biotech co-founded by Coinbase Global Inc. (Nasdaq: COIN) Chief Executive Brian Armstrong, has closed a $435 million Series C funding round, the company <\/span><span style=\"font-weight:400\">announced on June 2<\/span><span style=\"font-weight:400\">. The raise was <\/span><a href=\"https:\/\/blog.newlimit.com\/p\/newlimit-raises-435m-led-by-founders\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight:400\">led by Founders Fund<\/span><\/a><span style=\"font-weight:400\"> and roughly tripled<\/span><span style=\"font-weight:400\"> Newlimit\u2019s <\/span><span style=\"font-weight:400\">post-money valuation to about<\/span><span style=\"font-weight:400\"> $3.1 billion, up from a mark that sat below $1 billion at its previous round.<\/span><\/p>\n<figure id=\"attachment_819676\" aria-describedby=\"caption-attachment-819676\" style=\"width:733px\" class=\"wp-caption aligncenter\"><figcaption id=\"caption-attachment-819676\" class=\"wp-caption-text\">Image source: X<\/figcaption><\/figure>\n<p><span style=\"font-weight:400\">The financing drew a roster of high-profile backers, including new investors like Thrive Capital, Greenoaks, and Quiet Capital. Returning supporters included Kleiner Perkins, Abstract, and Valor Equity Partners, each of whom added to their existing stakes. <\/span><\/p>\n<p><span style=\"font-weight:400\">Founded in 2021 by Armstrong, former GV partner and bioengineer Blake Byers, and stem cell biologist Mark Kimmel, Newlimit is built on a single thesis, i.e. aging is \u201cplastic,\u201d or reversible, at the cellular level. The company develops medicines designed to restore youthful function to old cells through epigenetic reprogramming, a technique that aims to reset how genes are expressed without altering the underlying DNA.<\/span><\/p>\n<h2><span style=\"font-weight:400\">From a Side Project to a $3 Billion Bet<\/span><\/h2>\n<p><span style=\"font-weight:400\">Newlimit has grown quickly and the numbers spell that quite clearly. The startup raised <\/span><span style=\"font-weight:400\">$130 million as recently as last year<\/span><span style=\"font-weight:400\">, meaning the new round more than triples its valuation in roughly twelve months. The company has said the accelerated timeline was driven by a prototype medicine breakthrough that reverses cell age in old human liver cells, giving the team confidence to push toward the clinic.<\/span><\/p>\n<p><span style=\"font-weight:400\">That progress sets up the company\u2019s most important milestone yet, as Newlimit said it plans to bring its first aging-reprogramming medicine into <\/span><a href=\"https:\/\/www.statnews.com\/2026\/06\/02\/longevity-startup-newlimit-announces-435-million-clinical-trial-financing\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight:400\">human clinical trials next year<\/span><\/a><span style=\"font-weight:400\">, a step that will move the firm from laboratory research into regulated drug development.<\/span><\/p>\n<p><span style=\"font-weight:400\">Moreover, epigenetic reprogramming, the science underpinning Newlimit, has become one of the most closely watched and heavily funded areas of biotechnology. The approach builds on Nobel-winning research showing that mature cells can be coaxed back toward a younger state, and a wave of startups has raced to turn that insight into therapies. Newlimit\u2019s latest raise places it among the best-capitalized names in the field.<\/span><\/p>\n<h2><span style=\"font-weight:400\">Armstrong\u2019s Expanding Footprint<\/span><\/h2>\n<p><span style=\"font-weight:400\">For Armstrong, the round highlights a portfolio that now stretches well beyond Coinbase. He has used his <a href=\"http:\/\/www.bitcoin.com\/get-started\/a-quick-introduction-to-crypto\/\" class=\"lar_link lar_link_outgoing\" target=\"_blank\" rel=\"noopener noreferrer\">crypto<\/a> fortune to back ambitious science and infrastructure projects, framing longevity as one of the defining technological challenges of the era. <a href=\"https:\/\/www.bitcoin.com\/\" class=\"lar_link lar_link_outgoing\" target=\"_blank\" rel=\"noopener noreferrer\">Bitcoin.com<\/a> News has reported on Armstrong\u2019s running commentary about modernizing finance and <\/span><a href=\"https:\/\/news.bitcoin.com\/coinbase-ceo-onchain-economy-has-reached-escape-velocity-amid-generational-shift\/\"><span style=\"font-weight:400\">the broader onchain economy<\/span><\/a><span style=\"font-weight:400\">, and his biotech bet runs on a parallel track of long-horizon, high-risk investing.<\/span><\/p>\n<p><span style=\"font-weight:400\">The Founders Fund-led round also reflects renewed investor appetite for moonshot biotech at a time when <a href=\"http:\/\/www.bitcoin.com\/get-started\/a-quick-introduction-to-crypto\/\" class=\"lar_link lar_link_outgoing\" target=\"_blank\" rel=\"noopener noreferrer\">crypto<\/a> markets have been wobbling. Backers are betting that breakthroughs in cellular reprogramming could eventually produce treatments for age-related disease, a market measured in the trillions if the science delivers.<\/span><\/p>\n<p><span style=\"font-weight:400\">The next test is the clinic and Newlimit\u2019s move into human trials next year will be the first real-world read on whether its laboratory results translate into safe, effective medicines.<\/span><\/p>\n<\/p><\/div>\n<p><a href=\"https:\/\/news.bitcoin.com\/newlimit-435-million-series-c-brian-armstrong\/\">Source link <\/a><br \/>\n<br \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Originally posted on : Bitcoin News ) Key Takeaways Newlimit raised a $435 million Series C led by Founders Fund, announced June 2. The round lifted the biotech\u2019s valuation to about $3.1 billion, roughly triple its prior mark. Newlimit plans to bring its first cell-aging reprogramming medicine into human trials next year. Crypto Wealth Flows [&hellip;]<\/p>\n","protected":false},"author":3947362404,"featured_media":73484,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[32],"tags":[],"_links":{"self":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/posts\/73483"}],"collection":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/users\/3947362404"}],"replies":[{"embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/comments?post=73483"}],"version-history":[{"count":0,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/posts\/73483\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/media\/73484"}],"wp:attachment":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/media?parent=73483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/categories?post=73483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/tags?post=73483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}